Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.

Piché N, Leblond FA, Sidéris L, Pichette V, Drolet P, Fortier LP, Mitchell A, Dubé P.

Ann Surg. 2011 Jul;254(1):138-44. doi: 10.1097/SLA.0b013e3182193143.

PMID:
21494122
2.

Reply to Letter: "Rationale for Heating Oxaliplatin for the Intraperitoneal Treatment of Peritoneal Carcinomatosis".

Sideris L, Drolet P, Mitchell A, Dubé P.

Ann Surg. 2016 Apr;263(4):e60-1. doi: 10.1097/SLA.0000000000001027. No abstract available.

PMID:
26636241
3.

About the Rationale for Heating Oxaliplatin During HIPEC.

Ortega-Deballon P, Facy O, Rat P, Chauffert B.

Ann Surg. 2016 Apr;263(4):e60. doi: 10.1097/SLA.0000000000000347. No abstract available.

PMID:
24169194
4.

Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.

Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH.

J Surg Oncol. 2001 Feb;76(2):106-14.

PMID:
11223836
6.

High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.

Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P.

Ann Surg. 2012 Dec;256(6):1084-8. doi: 10.1097/SLA.0b013e3182582b38.

PMID:
22634898
7.

Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.

Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M.

Ann Oncol. 2002 Feb;13(2):267-72.

PMID:
11886004
8.

Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.

Pérez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farré-Alegre J, Pérez-Ruixo JJ.

Cancer Chemother Pharmacol. 2013 Mar;71(3):693-704. doi: 10.1007/s00280-012-2060-2.

PMID:
23274396
9.

[Intraperitoneal chemotherapy with oxaliplatin after complete cytoreduction for peritoneal carcinomatosis from colorectal carcinoma: preliminary experience].

Mura G, Framarini M, Milandri C, Rosetti P, Vagliasindi A, Solfrini G, Mazza P, Verdecchia GM.

Suppl Tumori. 2005 May-Jun;4(3):S111-2. Italian.

PMID:
16437938
10.

Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.

Valenzuela B, Nalda-Molina R, Bretcha-Boix P, Escudero-Ortíz V, Duart MJ, Carbonell V, Sureda M, Rebollo JP, Farré J, Brugarolas A, Pérez-Ruixo JJ.

AAPS J. 2011 Mar;13(1):72-82. doi: 10.1208/s12248-010-9249-2. Erratum in: AAPS J. 2011 Jun;13(2):318.

11.

Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model.

Badrudin D, Perrault-Mercier C, Bouchard-Fortier A, Hubert J, Leblond FA, Sideris L, Dubé P.

Surg Oncol. 2016 Dec;25(4):435-440. doi: 10.1016/j.suronc.2016.05.014.

PMID:
27251757
12.

HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.

Elias D, Pocard M, Goere D.

Cancer Treat Res. 2007;134:303-18. No abstract available.

PMID:
17633062
13.

Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN.

Ann Surg Oncol. 2013 Apr;20(4):1101-4. doi: 10.1245/s10434-012-2790-8.

14.

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.

Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P.

Ann Surg Oncol. 2008 Feb;15(2):535-41.

PMID:
17960463
15.

Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.

Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, Lasser P, Laurent S, Bourget P.

Oncology. 2002;63(4):346-52.

PMID:
12417789
16.

Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.

Srinivas NR.

Eur J Clin Pharmacol. 2009 Mar;65(3):321-2. doi: 10.1007/s00228-008-0585-4. No abstract available.

PMID:
19011850
17.

A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.

Stewart JH 4th, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, Levine KE, Jones BT, Levine EA.

Ann Surg Oncol. 2008 Aug;15(8):2137-45. doi: 10.1245/s10434-008-9967-1. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2421.

18.

The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.

Hompes D, D'Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V.

J Surg Oncol. 2014 May;109(6):527-32. doi: 10.1002/jso.23546.

PMID:
24375059
19.

Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.

Ceelen W, De Somer F, Van Nieuwenhove Y, Vande Putte D, Pattyn P.

Eur J Surg Oncol. 2013 Jul;39(7):754-9. doi: 10.1016/j.ejso.2012.07.120.

PMID:
22878060
20.

Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.

Pérez-Ruixo C, Peris JE, Escudero-Ortiz V, Bretcha-Boix P, Farré-Alegre J, Pérez-Ruixo JJ, Valenzuela B.

Cancer Chemother Pharmacol. 2014 May;73(5):1009-20. doi: 10.1007/s00280-014-2436-6.

PMID:
24663502
Items per page

Supplemental Content

Support Center